NanoM Wafer™ Ocular Insert

Integral BioSystems has developed NanoM Wafer™,  a bioengineered ocular insert, as a platform technology and patented them in global jurisdictions. We invite collaborations with pharmaceutical companies to render repurposed drugs IP-protectable with Integral’s proprietary drug delivery licensable innovation NanoM Wafer™. With multiple billion-dollar drug products going off-patent, a 505(b)(2) regulatory strategy presents a cost-effective way to develop an extended product life cycle with novel IP. Contact us for a discussion.

Benefits of Ocular Inserts Compared to Eye-drops

Attributes Eyedrops Ocular Insert
Efficiency of absorption Low absorption; losses due to lacrimal drainage Higher efficiency—residence time on eye driven by residence time of polymers in insert
Bioavailability Low, due to losses Bioavailability can be enhanced by longer residence time afforded by dissolving inserts
Preservative Preservative-free requires specialty CC No preservative required
Stability Formulation composition dependent Stability is greatly enhanced due to dry physical state
Flexibility of dosing Higher drug concentrations can be limited by drug  solubility Higher doses feasible in inserts
Combination drugs Drugs combined in solution may be incompatible chemically Co-incorporation of incompatible drugs
Self-Administered Yes Yes
Manufacturing Established Technology IP-dependent, but manufacturable
Packaging LDPE eye-dropper Peel-pouch, applicator
Sustained release Low, or none Highly versatile; ocular inserts can be designed to modulate release

NanoM Wafer™: A Bioengineered Ocular Insert

bioadhesive wafer how it works
  • Dimensions : fits comfortably under lower eyelid
  • Placement: placed in lower conjunctival fornix
  • Turns into a translucent hydrogel upon hydration
  • Fluids permeable (O2, CO2, H2O)
  • >90% H2O
  • Biodegradable

Value Proposition

Intellectual Property

  • Family of patents in 12 global jurisdictions
  • Platform technology
  • IP covers both dissolvable and non-dissolvable wafers
  • IP covers sustained release of drugs
  • IP covers wafers with, and without drugs

Dissolvable Wafer: Applications in Ophthalmology

  • Dry Eye
  • Allergic Conjunctivitis
  • Prevention of Inflammation post-cataract surgery
  • Redness Reduction
  • Ocular Pain

Removable Wafer for Sustained Release: Applications in Ophthalmology

  • Sustained delivery for ocular disorders

Wafer Applications (Other Routes)

  • Women’s Health
  • Urologic
  • Sinusoidal
  • Sublingual
  • Dermal

Dissolution Time of Dissolvable Wafer Can Be Modulated by Composition

The intricate fenestrations of the NanoM Wafer™ offer high contact  with mucosal tissue, establishing mucoadhesive bonds.

  • Rapid hydration
  • “sinks” into tissue, while dissolving
dissolution time of wafer

NanoM Wafer™ Patent Granted in Global Jurisdictions

Platform Delivery System: w/ and w/o API, intercalation of neutral and mucoadhesive fibers formed by electrospinning, thickness 1-1000 nm, flexural modulus < 30 MPa

  • NanoM Wafer trademark filed and in-use
  • Fully Patented; patent life until 2035
  • Wholly owned by Symphony parent company, Integral BioSystems
  • Broad IP scope
  • Both Composition and Process IP
  • Patented in USA, Canada, Great Britain, France, Italy, Germany, Spain, India, Singapore, China, Japan, Australia, New Zealand, South Africa
  • Additional evolving IP filed

NanoM Wafer™ products currently in co-development. Call Integral today for a collaboration.